C4 therapeutics reports first quarter 2024 financial results and recent business highlights

Successfully delivered first development candidate to biogen; $8 million payment earned established a strategic discovery research collaboration with merck kgaa, darmstadt, germany, focused on two critical oncogenic proteins progressed phase 1 dose escalation trials for cemsidomide (cft7455) and cft1946; data from both trials expected in 2h 2024 cash, cash equivalents and marketable securities total $299.2 million as of march 31, 2024; expected to provide runway into 2027 watertown, mass., may 08, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended march 31, 2024, as well as recent business highlights.
CCCC Ratings Summary
CCCC Quant Ranking